摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-(trifluoromethyl)isobenzofuran-1(3H)-one | 481075-47-2

中文名称
——
中文别名
——
英文名称
6-(trifluoromethyl)isobenzofuran-1(3H)-one
英文别名
6-(trifluoromethyl)phthalide;6-trifluoromethyl-3H-isobenzofuran-1-one;6-(trifluoromethyl)-3H-2-benzofuran-1-one
6-(trifluoromethyl)isobenzofuran-1(3H)-one化学式
CAS
481075-47-2
化学式
C9H5F3O2
mdl
——
分子量
202.133
InChiKey
GKNSPAIMGVILDM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    304.1±42.0 °C(Predicted)
  • 密度:
    1.448±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    14
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    6-(trifluoromethyl)isobenzofuran-1(3H)-oneN-溴代丁二酰亚胺(NBS)偶氮二异丁腈三乙酰氧基硼氢化钠三乙胺N,N-二甲基甲酰胺三氟乙酸三氯氧磷 作用下, 以 乙醇二氯甲烷异丙醇 为溶剂, 反应 24.0h, 生成 N-[1-[4-hydroxy-4-(1,3-thiazol-5-yl)cyclohexyl]azetidin-3-yl]-2-[[7-(trifluoromethyl)phthalazin-1-yl]amino]acetamide
    参考文献:
    名称:
    A novel series of N-(azetidin-3-yl)-2-(heteroarylamino)acetamide CCR2 antagonists
    摘要:
    The inflammatory response associated with the activation of C C chemokine receptor CCR2 via it's interaction with the monocyte chemoattractant protein-1 (MCP-1, CCL2) has been implicated in many disease states, including rheumatoid arthritis, multiple sclerosis, atherosclerosis, asthma and neuropathic pain. Small molecule antagonists of CCR2 have been efficacious in animal models of inflammatory disease, and have been advanced into clinical development. The necessity to attenuate hERG binding appears to be a common theme for many of the CCR2 antagonist scaffolds appearing in the literature, presumably due the basic hydrophobic motif present in all of these molecules. Following the discovery of a novel cyclohexyl azetidinylamide CCR2 antagonist scaffold, replacement of the amide bond with heterocyclic rings was explored as a strategy for reducing hERG binding and improving pharmacokinetic properties. (C) 2012 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2012.12.017
  • 作为产物:
    描述:
    6-氨基四氯苯酞盐酸copper(l) iodide 、 sodium nitrite 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 18.0h, 生成 6-(trifluoromethyl)isobenzofuran-1(3H)-one
    参考文献:
    名称:
    A novel series of N-(azetidin-3-yl)-2-(heteroarylamino)acetamide CCR2 antagonists
    摘要:
    The inflammatory response associated with the activation of C C chemokine receptor CCR2 via it's interaction with the monocyte chemoattractant protein-1 (MCP-1, CCL2) has been implicated in many disease states, including rheumatoid arthritis, multiple sclerosis, atherosclerosis, asthma and neuropathic pain. Small molecule antagonists of CCR2 have been efficacious in animal models of inflammatory disease, and have been advanced into clinical development. The necessity to attenuate hERG binding appears to be a common theme for many of the CCR2 antagonist scaffolds appearing in the literature, presumably due the basic hydrophobic motif present in all of these molecules. Following the discovery of a novel cyclohexyl azetidinylamide CCR2 antagonist scaffold, replacement of the amide bond with heterocyclic rings was explored as a strategy for reducing hERG binding and improving pharmacokinetic properties. (C) 2012 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2012.12.017
点击查看最新优质反应信息

文献信息

  • COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS
    申请人:Carroll William A.
    公开号:US20100249129A1
    公开(公告)日:2010-09-30
    Disclosed herein are compounds of formula (I) wherein Ring A and R 1 are as defined in the specification. Pharmaceutical compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and pharmaceutical compositions are also disclosed.
    本文揭示了以下式(I)的化合物 其中环A和R 1 如规范中所定义。还披露了包含这些化合物的药物组合物,以及使用这些化合物和药物组合物治疗疾病和疾病的方法。
  • Conversion of Aromatic Amino into Trifluoromethyl Groups through a Sandmeyer­-Type Transformation
    作者:Jianbo Wang、Xi Wang、Yan Xu、Yujing Zhou、Yan Zhang
    DOI:10.1055/s-0033-1338659
    日期:——
    strategy for aromatic trifluoromethylation by converting amino into trifluoromethyl groups via a Sandmeyer-type reaction is reported. The transformation involves diazotization of the aromatic amines with tert-butyl nitrite and hydrochloric acid to form aryldiazonium chlorides, followed by trifluoromethylation with trifluoromethylsilver at low temperature. Various readily available aromatic amines are
    摘要 报道了通过Sandmeyer型反应将氨基转化为三氟甲基的芳香族三氟甲基化的新策略。该转化包括用亚硝酸叔丁酯和盐酸将芳族胺重氮化以形成芳基重氮氯化物,然后在低温下用三氟甲基银进行三氟甲基化。各种容易获得的芳族胺在温和条件下均能平稳转化。 报道了通过Sandmeyer型反应将氨基转化为三氟甲基的芳香族三氟甲基化的新策略。该转化包括用亚硝酸叔丁酯和盐酸将芳族胺重氮化以形成芳基重氮氯化物,然后在低温下用三氟甲基银进行三氟甲基化。各种容易获得的芳族胺在温和条件下均能平稳转化。
  • [EN] CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2<br/>[FR] ANTAGONISTES DU CCR2 À BASE DE CYCLOHEXYL-AZÉTIDINYLE
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:WO2011159854A1
    公开(公告)日:2011-12-22
    The present invention comprises compounds of Formula (I). Wherein: R1, R2, R4, J, Q, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).
    本发明包括公式(I)的化合物。其中:R1、R2、R4、J、Q和A如说明书所述定义。本发明还包括预防、治疗或改善综合征、障碍或疾病的方法,其中所述综合征、障碍或疾病为2型糖尿病、肥胖和哮喘。本发明还包括通过管理治疗有效量的至少一种公式(I)化合物来抑制哺乳动物中的CCR2活性的方法。
  • Visible Light-Promoted Magnesium, Iron, and Nickel Catalysis Enabling C(sp<sup>3</sup>)–H Lactonization of 2-Alkylbenzoic Acids
    作者:Sasa Li、Mincong Su、Jie Sun、Kunjun Hu、Jian Jin
    DOI:10.1021/acs.orglett.1c01984
    日期:2021.8.6
    patterns could be transformed into the corresponding phthalide products. Based on the mechanistic experimentation and reported prior studies, a possible mechanism for the benzylic oxidative lactonization reaction was proposed with the hypothetic photoactive ternary complex formed between the 2-alkylbenzoic acid substrate, magnesium ion, and bromate anion.
    通过合并光催化和镁(铁、镍)催化,实现了温和实用的 C(sp 3 )-H 内酯化方案。具有多种取代模式的多种 2-烷基苯甲酸可以转化为相应的邻苯二甲酸产品。基于机理实验和先前报道的研究,提出了苄基氧化内酯化反应的可能机制,假设光活性三元络合物在 2-烷基苯甲酸底物、镁离子和溴酸盐阴离子之间形成。
  • Squaramide-Catalyzed Asymmetric Intramolecular Oxa-Michael Reaction of α,β-Unsaturated Carbonyls Containing Benzyl Alcohol: Construction of Chiral 1-Substituted Phthalans
    作者:Eun Chae Son、Seung Yeon Kim、Sung-Gon Kim
    DOI:10.1021/acs.joc.1c00715
    日期:2021.5.7
    intramolecular oxa-Michael reactions of benzyl alcohol bearing α,β-unsaturated carbonyls as Michael acceptors are presented herein. Using cinchona squaramide-based organocatalyst, enones as well as α,β-unsaturated esters containing benzyl alcohol provided their corresponding 1,3-dihydroisobenzofuranyl-1-methylene ketones and 1,3-dihydroisobenzofuranyl-1-methylene esters in excellent yields with high
    本文介绍了带有α,β-不饱和羰基的苄醇作为迈克尔受体的有机催化对映选择性分子内氧杂-迈克尔反应。使用基于金鸡纳酸方酰胺的有机催化剂,烯酮以及含苄醇的α,β-不饱和酯可提供其相应的1,3-二氢异苯并呋喃基-1-亚甲基酮和1,3-二氢异苯并呋喃基-1-亚甲基酯,且具有高对映选择性。另外,可以从1,3-二氢-2-苯并呋喃-1-醇的Wittig / oxa-Michael反应级联获得对映体富集的1,3-二氢异苯并呋喃基-1-亚甲基酮。
查看更多